ArticleCurrent neuropharmacology2008
Dopaminergic and noradrenergic contributions to functionality in ADHD: the role of methylphenidate.
Article in Current neuropharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Systematic review of animal studies on the use of herbal medicine for attention-deficit/hyperactivity disorder.Frontiers in psychiatry · 2026Pooled it
- Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).The Cochrane database of systematic reviews · 2023Pooled it
- Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.The Cochrane database of systematic reviews · 2021Pooled it
- Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.The Cochrane database of systematic reviews · 2018Pooled it
- Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).The Cochrane database of systematic reviews · 2015Pooled it
- Bayesian dynamical system analysis of the effects of methylphenidate in children with attention-deficit/hyperactivity disorder: a randomized trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Trial
- Methylphenidate Enhances Spontaneous Fluctuations in Reward and Cognitive Control Networks in Children With Attention-Deficit/Hyperactivity Disorder.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2023Trial
- The effects of methylphenidate on whole brain intrinsic functional connectivity.Human brain mapping · 2014Trial
- The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial.Orphanet journal of rare diseases · 2014Trial
- Trial
- Cell-Type-Specific WTAP and ALKBH5-Mediated mCNS neuroscience & therapeutics · 2026Article
- Concomitant activation of DResearch square · 2026Article
- Concomitant activation of DDiscover pharmaceutical sciences · 2026Article
- New frontiers in pharmacological treatment of attention-deficit hyperactivity disorder.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Alterations in Corneal Morphology and Thickness Associated with Methylphenidate Treatment in Children with Attention-Deficit/Hyperactivity Disorder.Diagnostics (Basel, Switzerland) · 2025Article
- Increased Recall of Negative Memories Following Initial Methylphenidate Administration in a 6-Year-Old Boy With ADHD: A Case Report.Neuropsychopharmacology reports · 2025Article
- Genomic factors associated with substance use disorder relapse: A critical review.Addictive behaviors reports · 2024Review
- Decrease in decision noise from adolescence into adulthood mediates an increase in more sophisticated choice behaviors and performance gain.PLoS biology · 2024Article
- Comorbid ADHD and schizophrenia and the use of psychostimulants: a scoping review protocol.BMJ open · 2024Article
- Investigating the Impact of Nutrition and Oxidative Stress on Attention Deficit Hyperactivity Disorder.Nutrients · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Attention Deficit Hyperactivity Disorder (ADHD) is a childhood psychiatric condition characterized by severe impulsiveness, inattention and overactivity. Methylphenidate (MPH), a psychostimulant affecting both the dopaminergic and the noradrenergic systems, is one of the most frequently prescribed treatments for ADHD. Despite the widespread use of MPH and its proven effectiveness, its precise neurochemical mechanisms of action are under debate. For the most part, MPH's influence on subcortical dopamine neurotransmission is thought to play a crucial role in its behavioral and cognitive effects. In their hypothesis of biphasic MPH action, Seeman and Madras [42, 43] suggest that therapeutic doses of MPH elevate tonic dopamine while inhibiting phasic transmitter release in subcortical structures, leading to reduced postsynaptic receptor stimulation and psychomotor activation in response to salient stimuli. Volkow and colleagues [56] suggest that by amplifying a weak striatal dopamine signal, MPH increases the perception of a stimulus or task as salient. The enhanced interest for the task is thought to increase attention and improve performance. Recent animal studies have however shown that when administered at doses producing clinically relevant drug plasma levels and enhancing cognitive function, MPH preferentially activates dopamine and noradrenaline efflux within the prefrontal cortex relative to the subcortical structures [5]. Overall, we suggest that the delineated theories of MPH therapeutic action should not be discussed as exclusive. Studies are outlined that allow integrating the different findings and models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.